{"entity":{"id":"nct05868707","kind":"trial","name":"OH2 Injection in Melanoma","aka":[],"tldr":"A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","summary":"OH2 Injection in Melanoma is a phase 3 interventional study registered as NCT05868707 by Binhui Biopharmaceutical Co., Ltd., with 340 participants planned, started 2023-03-08 and due to reach its primary completion in 2026-03. Interventions recorded: OH2 and Salvage chemotherapy or best supportive care.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05868707","url":"https://clinicaltrials.gov/study/NCT05868707"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05868707","phase":"3","setting":"To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy","sponsor":"Binhui Biopharmaceutical Co., Ltd.","enrolled":340,"outcomes":[]},"route":"/trials/nct05868707/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/"}]}}